NASDAQ:SLN Silence Therapeutics Q2 2026 Earnings Report $11.51 -0.78 (-6.35%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$11.50 0.00 (-0.04%) As of 09/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Silence Therapeutics EPS ResultsActual EPS-$0.26Consensus EPS -$0.14Beat/MissMissed by -$0.12One Year Ago EPSN/ASilence Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.13 millionBeat/MissN/AYoY Revenue GrowthN/ASilence Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETUpcoming EarningsSilence Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (6-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Silence Therapeutics Earnings HeadlinesContrasting Absci (NASDAQ:ABSI) & Silence Therapeutics (NASDAQ:SLN)September 21 at 6:14 AM | americanbankingnews.comSilence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Silence Therapeutics: Making Some Recent NoiseAugust 19, 2026 | seekingalpha.comSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSsAugust 14, 2026 | businesswire.comAnalysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)August 12, 2026 | theglobeandmail.comSee More Silence Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email. Email Address About Silence TherapeuticsSilence Therapeutics (NASDAQ:SLN) plc is a biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its proprietary mRNAi GOLD platform is designed to identify and silence specific messenger RNA targets, with the aim of producing durable effects from infrequent dosing. The company’s pipeline includes zerlasiran, formerly known as SLN360, an investigational therapy designed to reduce production of lipoprotein(a), a genetically determined risk factor associated with cardiovascular disease. Silence is also developing additional RNA interference programs for conditions including hematologic and metabolic disorders. These candidates remain investigational and are subject to clinical and regulatory evaluation. Silence Therapeutics was established in the United Kingdom and has operations serving the international biotechnology and pharmaceutical markets. The company advances its own pipeline and has pursued collaborations and licensing arrangements intended to apply its RNAi platform to additional therapeutic targets. Its American Depositary Shares trade on the Nasdaq Global Select Market under the symbol SLN.View Silence Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
